3 Beaten-Down Stocks That Aren't Worth Buying on the Dip

Group 1: Tilray Brands - Tilray has been a speculative investment based on hopes for marijuana legalization in the U.S., but the stock has declined over 94% in five years [3][4] - The company has diversified into alcoholic beverages, yet its financial situation remains precarious, with a market cap below $1 billion [5] - Continuous cash burn and losses indicate a lack of recovery potential for Tilray [5] Group 2: Moderna - Moderna has missed opportunities to diversify beyond its COVID vaccine revenue, focusing instead on COVID-related products [6] - The company expects revenue between$1.5 billion and $2.5 billion for the year, a reduction of approximately$1 billion from previous expectations [8] - There are no clear catalysts for growth, making it a stock to avoid even if prices decline further [9] Group 3: Plug Power - Plug Power's stock has plummeted from over $70 in 2021 to under$2, reflecting investor skepticism [10] - The company faces significant financial challenges, with $94 million in cash and operating losses exceeding$720 million in the first nine months of 2024 [12] - The sustainability of its operations is in question, suggesting that investors should consider other growth opportunities [12]